Sanofi (SNY) said Thursday it plans to purchase Dren Bio's experimental autoimmune treatment DR-0201 for $600 million.
The deal, which is expected to close in Q2, also includes up to $1.3 billion in milestone-based payments tied to development progress and potential product launches, the company said.
DR-0201 is a bispecific antibody meant to engage myeloid cells and remove B cells, a mechanism believed to help reset the immune system in hard-to-treat autoimmune disorders.
The drug is currently being tested in two phase 1 trials and has shown early signals of effectiveness in both lab and clinical research, Sanofi said.
The company's shares were down almost 0.5% in recent Thursday premarket activity.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。